Project Grant R01AI177615
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $441,204 to the University of California, Davis on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on preventing invasive candidiasis caused by Candida albicans. The project, which runs through January 31, 2028, focuses on understanding and restoring gastrointestinal microbiota-host interactions to prevent the dissemination of C....
- Federal Project Grant Award Summary Mayo Clinic received a $443,850 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 4, 2026, with a completion date of January 31, 2028. The award supports research investigating how intestinal exposure to Candida albicans in early life influences developing immune system responses, specifically T cell responses and the...
- Federal Project Grant Award Summary Brown University received a $151,040 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 20, 2026, with completion targeted for October 31, 2027. The award supports investigator-initiated research investigating the evolutionary rewiring of transcriptional circuits that confer azole drug resistance in Candida auris, an emerging...
- This $500,902 National Science Foundation project grant supports research into polyamine regulated morphogenesis in the fungal pathogen Candida albicans at Texas A&M International University from August 15, 2022 to July 31, 2025. The grant falls under the NSF Biological Sciences program (CFDA 47.074), which aims to increase scientific knowledge and understanding of major biological problems. The university will investigate the molecular mechanisms by which polyamines regulate fungal growth...
- Federal Project Grant Award Summary New York University School of Medicine received a $416,664 project grant awarded on June 16, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research through May 31, 2030, investigating host-pathogen interactions during Staphylococcus aureus spine infections. The research addresses a significant clinical challenge, as S. aureus is the...
- FEDERAL PROJECT GRANT AWARD SUMMARY The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $188,916 Project Grant to Brigham & Women's Hospital Inc. (Department of Faulkner Pathology) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with a completion date of July 31, 2030. This research project investigates how noncytotoxic Staphylococcus aureus evades detection and clearance by the innate immune system, with particular...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Texas A&M University System Health Science Center a $192,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective June 1, 2026, with a completion date of May 31, 2028. The award funds research to develop novel antifungal therapeutics targeting inositol lipid signaling pathways in drug-resistant fungal species, specifically Candida auris and...
- Federal Project Grant Award Summary Massachusetts Institute of Technology received a $172,028 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop innovative therapeutics targeting invasive fungal infections, particularly Candida auris. The award, dated June 1, 2026, with completion targeted for May 31, 2028, funds research to create "cellular glues"—multivalent ligand...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $4.41 million through the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center for the "Deciphering Immunopathogenesis of Mucormycosis to Advance Risk Stratification, Diagnosis and Management of the Disease" (MUCOR-ADVANCE) project. This five-year Program Project Grant, effective July 1,...
- Federal Project Grant Award Summary The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center received a $245,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 14, 2025, with completion targeted for June 30, 2027. The grant supports the development and characterization of a novel mouse model of neonatal fungal colonization to investigate immune...
FUNGAL-BACTERIAL DYNAMICS DRIVING DYSREGULATED HOST RESPONSES AND LETHAL SYNERGISM - POLYMICROBIAL INFECTIONS INVOLVING FUNGAL AND BACTERIAL PATHOGENS ARE INCREASINGLY COMMON AMONG HOSPITALIZED PATIENTS. HOWEVER, THERE IS A PAUCITY OF RESEARCH FOCUSED ON STUDYING POLYMICROBIAL INFECTIONS. THE FUNGAL PATHOGEN CANDIDA ALBICANS IS THE MOST COMMON CAUSE OF INVASIVE FUNGAL INFECTION AND THE THIRD MOST COMMON CAUSE OF NOSOCOMIAL BLOODSTREAM INFECTIONS IN THE US. INVASIVE FUNGAL INFECTIONS WITH C. ALBICANS HAVE DEVASTATINGLY HIGH MORTALITY RATES COMPARED WITH BACTERIAL INFECTIONS. BLOODSTREAM FUNGAL INFECTIONS, WHICH ARE MOSTLY MONOMICROBIAL, RESULT IN A 40% MORTALITY RATE. IN CONTRAST, INTRA-ABDOMINAL FUNGAL INFECTIONS (IAI), WHICH ARE OFTEN POLYMICROBIAL INVOLVING BOTH FUNGAL AND BACTERIAL SPECIES, RESULT IN A 50-75% MORTALITY RATE, WHICH FAR EXCEEDS BACTERIAL MONO- OR POLYMICROBIAL IAI MORTALITY RATES (20%). FUNGAL INVOLVEMENT ALSO LEADS TO INCREASED RATES OF RELAPSE AND MORE SEVERE DISEASE SCORES. THE MECHANISMS ASSOCIATED WITH THIS EXACERBATED MORTALITY ARE CURRENTLY UNKNOWN. THE OBJECTIVE OF THIS PROPOSAL IS TO DELINEATE HOST AND MICROBIAL MECHANISMS CONTRIBUTING TO SYNERGISTIC LETHALITY DURING POLYMICROBIAL FUNGAL-BACTERIAL IAI. OUR CENTRAL HYPOTHESIS IS THAT POLYMICROBIAL FUNGAL-BACTERIAL IAIS PROMOTE SYNERGISTIC EFFECTS ON MORTALITY INDUCED BY MICROBE-MICROBE INTERACTIONS THAT INCREASE BACTERIAL TOXIN PRODUCTION, LEADING TO UPREGULATION OF IMMUNE SIGNALING PATHWAYS, DYSREGULATION OF HEMOSTASIS AND COAGULATION, AND ALTERED BONE MARROW REMODELING. THIS HYPOTHESIS WILL BE TESTED BY MODELING POLYMICROBIAL INTERACTIONS WITH C. ALBICANS AND THE GRAM-POSITIVE BACTERIUM STAPHYLOCOCCUS AUREUS, WHICH IS THE MOST COMMONLY CO-ISOLATED BACTERIAL PATHOGEN FROM FUNGAL-BACTERIAL CO-INFECTIONS. THE FIRST SPECIFIC AIM OF THIS PROJECT IS TO INTERROGATE THE MECHANISMS BY WHICH CANDIDA INDUCES OF S. AUREUS TOXIN PRODUCTION DURING POLYMICROBIAL IAI. THE SECOND SPECIFIC AIM WILL DEFINE BACTERIAL MECHANISMS AND VIRULENCE REGULATORS THAT DRIVE DYSREGULATED HEMOSTASIS AND COAGULATION THAT CONTRIBUTE TO LETHALITY DURING POLYMICROBIAL IAI. THE THIRD SPECIFIC AIM WILL FUNCTIONALLY CHARACTERIZE THE CONSEQUENCES OF CANDIDA-INDUCED S. AUREUS TOXIN PRODUCTION ON BONE MARROW HOMEOSTASIS AND TRAINED INNATE IMMUNITY. COMPLETION OF THIS PROJECT WILL IDENTIFY BOTH NEW MECHANISMS THAT UNDERLIE EXACERBATED PATHOGENICITY OF POLYMICROBIAL INFECTIONS AND THERAPEUTIC APPROACHES TO IMPROVE OUTCOMES OF IAI.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $785.9k | 7/18/25 | ||
| Not listed | $822.6k | 7/15/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
260406S | Vanderbilt University Medical Center | Project Grant R01AI177615 | $288.0k | 3/23/26 | |
250250S | Vanderbilt University | Project Grant R01AI177615 | $290.4k | 1/12/26 | |
250245LSUHSCS | Louisiana State University | Project Grant R01AI177615 | $249.9k | 1/9/26 | |
260339S | Louisiana State University | Project Grant R01AI177615 | $246.3k | 1/9/26 |